PCSK9 and neurocognitive function: Should it be still an issue after FOURIER and EBBINGHAUS results?
The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
The serine protease proprotein convertase subtilisin/kexin type 9 (PCSK9) modulates the levels of low-density lipoprotein cholesterol and cardiovascular risk. Potential risks of adverse neurological effects of intensive lipid-lowering treatment have been hypothesized, as cholesterol is a component of the central nervous system. Moreover, several observations suggest that PCSK9 might play a role in neurogenesis, neuronal migration and apoptosis. In rodents, increased expression of PCSK9 has been detected in specific areas of the central nervous system during embryonic development; also, PCSK9 modulates low-density lipoprotein receptor levels in the ischemic brain areas. Despite a putative participation of PCSK9 in nervous system physiology, the absence of PCSK9 in knockout mice or in humans with loss-of-function mutations of PCSK9 gene has not been linked to neurological alterations. In recent years, some concerns have been raised about the potential neurological side effects of cholesterol-lowering treatments and, more specifically of PCSK9 inhibitors. In this review, the evidence regarding the function of PCSK9 in neuron differentiation, apoptosis, and migration and in nervous system development and latest clinical trials evaluating the effects of PCSK9 inhibitors on neurocognitive function will be described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
Efficacy and Safety of Alirocumab in Reducing Lipids and Cardiovascular Events
Robinson, J. G., Farnier, M., Krempf, M., Bergeron, J., Luc, G., Averna, M., Stroes, E. S., Langslet, G., Raal, F. J., El Shahawy, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501031 · Cited by 2,296
Apoptosis in neurodegenerative disorders
Mattson, M. P. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35040009 · Cited by 1,605
Efficacy and Safety of Evolocumab in Reducing Lipids and Cardiovascular Events
Sabatine, M. S., Giugliano, R. P., Wiviott, S. D., Raal, F. J., Blom, D. J., Robinson, J., Ballantyne, C. M., Somaratne, R., Legg, J., Wasserman, S. M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500858 · Cited by 1,509
Seidah, N. G., Benjannet, S., Wickham, L., Marcinkiewicz, J., Jasmin, S. B., Stifani, S., Basak, A., Prat, A., & Chrétien, M. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0335507100 · Cited by 1,191
Anti-PCSK9 Antibody Effectively Lowers Cholesterol in Patients With Statin Intolerance
Stroes, E., Colquhoun, D., Sullivan, D., Civeira, F., Rosenson, R. S., Watts, G. F., Bruckert, E., Cho, L., Dent, R., Knusel, B., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.03.019 · Cited by 526
Cognitive function in a randomized trial of evolocumab
Giugliano, R. P., Mach, F., Zavitz, K., Kurtz, C., Im, K., Kanevsky, E., Schneider, J., Wang, H., Keech, A., Pedersen, T. R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1701131 · Cited by 492
Status of computerized cognitive testing in aging: a systematic review
Wild, K., Howieson, D., Webbe, F., Seelye, A., & Kaye, J. (2008) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2008.07.003 · Cited by 436
Cited by
Targeting PCSK9 to tackle cardiovascular disease
Hummelgaard, S., Vilstrup, J. P., Gustafsen, C., Glerup, S., & Weyer, K. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108480 · Cited by 150
Mendelian Randomization Study of PCSK9 and HMG-CoA Reductase Inhibition and Cognitive Function
Rosoff, D. B., Bell, A. S., Jung, J., Wagner, J., Mavromatis, L. A., & Lohoff, F. W. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.05.041 · Cited by 126
Inclisiran—New hope in the management of lipid disorders?
Dyrbuś, K., Gąsior, M., Penson, P., Ray, K. K., & Banach, M. (2020) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2019.11.001 · Cited by 120
Self-citationO’Connell, E. M., & Lohoff, F. W. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.00609 · Cited by 93
Picard, C., Poirier, A., Bélanger, S., Labonté, A., Auld, D., Poirier, J., & on behalf of the PREVENT-AD Research Group (2019) · PLOS ONE · doi:10.1371/journal.pone.0220254 · Cited by 59
Risk of neuropsychiatric adverse effects of lipid-lowering drugs: a mendelian randomization study
Alghamdi, J., Matou-Nasri, S., Alghamdi, F., Alghamdi, S., Alfadhel, M., & Padmanabhan, S. (2018) · International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyy060 · Cited by 44
“Nevertheless, PCSK9 has been associated with several pleiotropic effects apart from their role in cholesterol traffickings, such as regulation of neuronal apoptosis, disposal of nonacetylated intermediates of the nascent membrane protein (BACE1), and degradation of other apolipoprotein E-binding receptors as well as p…”
BackgroundInsight into the Evolving Role of PCSK9
Maligłówka, M., Kosowski, M., Hachuła, M., Cyrnek, M., Bułdak, Ł., Basiak, M., Bołdys, A., Machnik, G., Bułdak, R. J., & Okopień, B. (2022) · Metabolites · doi:10.3390/metabo12030256 · Cited by 41
Proprotein convertase subtilisin/kexin type 9 (PCSK9) in the central nervous system
Bell, A. S., Wagner, J., Rosoff, D. B., & Lohoff, F. W. (2023) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2023.105155 · Cited by 36
Arunsak, B., Pratchayasakul, W., Amput, P., Chattipakorn, K., Tosukhowong, T., Kerdphoo, S., Jaiwongkum, T., Thonusin, C., Palee, S., Chattipakorn, N., et al. (2020) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2020.108470 · Cited by 19
PCSK9 deficiency alters brain lipid composition without affecting brain development and function
Pärn, A., Olsen, D., Tuvikene, J., Kaas, M., Borisova, E., Bilgin, M., Elhauge, M., Vilstrup, J., Madsen, P., Ambrozkiewicz, M. C., et al. (2023) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.1084633 · Cited by 16
“Our findings are in line with data from PCSK9 inhibitor clinical trials (Giugliano et al., 2017; Mannarino et al., 2018; Gencer et al., 2020; Ray et al., 2020) and from observations that people carrying loss-of-function mutations of the PCSK9 gene have no signs of neurological defects (Cohen et al.”
ResultYuet, W. C., Ebert, D., & Jann, M. (2021) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098620959271 · Cited by 8
Li, B., Chen, Y., Zhang, Y., Qian, M., Shan, Q., Qian, J., & Guo, J. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2468855 · Cited by 6
“Since cholesterol is an essential part of the neurological system and the brain creates its own cholesterol without regard to plasma lipid level, potential neurocognitive side effects have been hotly discussed [42].”
Simeone, P. G., Vadini, F., Tripaldi, R., Liani, R., Ciotti, S., Di Castelnuovo, A., Cipollone, F., & Santilli, F. (2021) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2021.632655 · Cited by 3
“Recently, some concerns have been raised about the potential neurological side effects of PCSK9 inhibitors, a class of drugs used as cholesterol-lowering treatments (Mannarino et al., 2018).”
Background
Metadata
- Authors
- Mannarino, M. R., Sahebkar, A., Bianconi, V., Serban, M.-C., Banach, M., & Pirro, M.
- Venue
- Journal of Clinical Lipidology
- Publisher
- Elsevier BV
- Published
- 2018-09
- Volume
- 12
- Issue
- 5
- Pages
- 1123-1132
- ISSN
- 1876-4789 (ISSN-L)
- 1933-2874
- OpenAlex
- W2807085521
- Cited by
- 48
- References
- 34
- FWCI
- 7.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.